US4150120A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Ophthalmic
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1977-12-29
•
Granted: 1979-04-17
•
Expires: 1997-12-29
Abstract
Abstract Eye diseases in mammals such as progressive cataract or conjunctivitis are effectively treated by administering to the mammals a thyroid stimulating hormone releasing hormone. The treatment effect is enhanced by the concomitant administration of the said hormone with an adrenocortica hormone.
Inventors
- 👤 Hiroomi Ono
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 13:46
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/04; A61K38/06; A61K38/066; A61P; A61P27/00; A61P27/02; A61P29/00; C; C07; C07K; C07K5/00; C07K5/04; C07K5/08; C07K5/0821; C07K5/0825
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
31 words
A method for treating an eye disease in a mammal, which comprises administering to the mammal an effective amount in an external dosage form of a thyroid stimulating hormone releasing hormone.
Claim 2
Independent Claim
31 words
A method for treating an eye disease in a mammal, which comprises administering to the mammal an effective amount in an external dosage form of a thyroid stimulating hormone releasing hormone.
Claim 3
Dependent Claim
18 words
A method as claimed in claim 1, wherein the eye disease is cataract or an inflammatory eye disease.
Claim 4
Dependent Claim
13 words
A method as claimed in claim 2, wherein the cataract is progressive cataract.
Claim 5
Dependent Claim
14 words
A method as claimed in claim 2, wherein the inflammatory eye disease is conjunctivitis.
Claim 6
Dependent Claim
23 words
A method as claimed in claim 1, wherein the thyroid stimulating hormone releasing hormone is in the form of a physiologically acceptable salt.
Claim 7
Dependent Claim
21 words
A method as claimed in claim 1, wherein the thyroid stimulating hormone releasing hormone is L-pyroglutamyl-L-histidyl-L-prolinamide or its physiologically acceptable salt.
Claim 8
Dependent Claim
14 words
A method as claimed in claim 6, wherein the physiologically acceptable salt is tartrate.
Claim 9
Dependent Claim
20 words
A method as claimed in claim 1, wherein the external dosage form is an ophthalmic solution or an ophthalmic ointment.
Claim 10
Dependent Claim
29 words
A method as claimed in claim 8, wherein the external dosage form contains the thyroid stimulating hormone releasing hormone in a concentration from about 0.001 to about 0.1 percent.
Claim 11
Dependent Claim
22 words
A method as claimed in claim 1, wherein the thyroid stimulating hormone releasing hormone is administered in conjunction with an adrenocortical hormone.
Claim 12
Dependent Claim
23 words
A method as claimed in claim 10, wherein the adrenocortical hormone is in the form of a physiologically acceptable ester or its salt.
Claim 13
Dependent Claim
15 words
A method as claimed in claim 10, wherein the adrenocortical hormone is dexamethasone or betamethasone.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-04-16 | 1982-10-16 | 1983-04-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-04-16 | 1986-10-16 | 1987-04-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-04-16 | 1990-10-16 | 1991-04-17 | $7700.00 | Window Closed / Lapsed |